ExactVu™ Micro-Ultrasound System Featured Prominently at 5th Multidisciplinary Meeting on Clinical Urology Conference in Bilbao, Spain

Multiple global speakers and live surgery illustrates the clinical benefit that the
ExactVu micro-ultrasound is bringing to improve prostate cancer detection

TORONTO and BILBAO, Spain, Feb. 22, 2018 /PRNewswire/ - At the 5^th Multidisciplinary Meeting on Clinical Urology - "The Dilemmas of Prostate Cancer: How to Improve Diagnosis", the ExactVu™ micro-ultrasound system is featured prominently as a new central tool for helping leading urology practices improve their visualization of the prostate and significantly improve their targeting of prostate biopsies. The conference, which is being held from February 22 - 23, 2018 at the Clínica IMQ Zorrotzaurre in Bilbao, Spain, is hosted by Dr. Ander Astobieta Odriozola. It brings together leading urologists from across Spain and Europe to discuss their new techniques and strategies to improve prostate cancer detection.

"In this fifth year for our Multidisciplinary Meeting on Clinical Urology congress, the ExactVu micro-ultrasound is being profiled because it is now a key component of our prostate cancer detection strategy as we are now able to actually see lesions and target our prostate biopsies," Dr. Ander Astobieta Odriozola, of IMQ, said. "No longer just new technology for ourselves and many of the clinical speakers at the event, the ExactVu platform now has the potential to change our standard of care and allow us to better target our biopsies to more efficiently, more effectively improve detection results and hopefully patient outcomes."

Clinical presentation at the congress on the ExactVu micro-ultrasound include the following:

• "High resolution ultrasound with 29 MHz" (Dr. José Gregorio Pereira),
• "Initial clinical experience with Micro-US in a real-life clinical scenario:
  the Humanitas research Hospital series" (Dr. Giovanni Lughezzani),
• "Prostate biopsy with Micro-Ultrasound: Our results" (Dr. Andrea Sánchez),
• "How to manage PI-RADS 3 lesions. Can enhanced TRUS solve the problem?" (Dr. Georg Salomon), and
• "Will ultrasound replace to magnetic resonance? What can be the current diagnostic algorithm?" (Moderators: Dr. José Gregorio Pereira / Dr. Georg Salomon).

There will also be a live broadcast of high resolution micro-ultrasound biopsy cases moderated by Dr. José Gregorio Pereira and the real-time micro-ultrasound targeted biopsy procedures being performed by Dr. Andrea Sánchez and Dr. Mikel Gamarra.

"With so much growing evidence for the ExactVu platform from multiple sites in so many different countries, it is exciting to see the rapid adoption of our new technology," Randy AuCoin, Exact Imaging's President and CEO, said. "The team at IMQ have been early adopters of our technology and have always had the highest standards in terms of patient care. Creating this Congress is another example of how they are creating open discourse amongst subject matter experts to share best practices, continually improve urological techniques and expertise, and ultimately improve outcomes. We are honored to be included in the clinical program and for our ExactVu platform to be part of their daily workflow for detecting prostate cancer."

The ExactVu micro-ultrasound and its newest feature, the FusionVu™ micro-ultrasound/MRI fusion application will also be on display in the exhibition area and demonstrated by Medicina Analitica Consumibles MAC S.A., a leading provider of clinical products and Exact Imaging's exclusive distributor of the ExactVu platform in Spain.

About Exact Imaging:
Exact Imaging (www.exactimaging.com) is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas, aided by the PRI-MUS™ (prostate risk identification using micro-ultrasound) evidence-based micro-ultrasound protocol. For the minority of cases where MRI might assist (i.e., prior negative biopsies), FusionVu™ is the forthcoming micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform. The ExactVu micro-ultrasound system has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

SOURCE Exact Imaging

Related Links

www.exactimaging.com